Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review
CONCLUSION: -: The contribution of improved glucose control in cardiovascular protection is limited, but is much greater for GLP-1RAs than for SGLT2is. Of note, such mediation or meta-regression analyses are exploratory and can only be viewed as hypothesis generating.PMID:38158077 | DOI:10.1016/j.diabet.2023.101508 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 29, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine
CONCLUSIONS: This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.PMID:38141807 | DOI:10.1016/j.diabet.2023.101507 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Youssef Kouidrat Lauriane Le Collen Martine Vaxillaire Aur élie Dechaume B énédicte Toussaint Emmanuel Vaillant Souhila Amanzougarene Mehdi Derhourhi Brigitte Delemer Mustapha Azahaf Philippe Froguel Am élie Bonnefond Source Type: research
Steatotic liver disease, MASLD and risk of chronic kidney disease
Diabetes Metab. 2023 Dec 21:101506. doi: 10.1016/j.diabet.2023.101506. Online ahead of print.ABSTRACTWith the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term nonalcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclatur...
Source: Diabetes and Metabolism - December 23, 2023 Category: Endocrinology Authors: Josh Bilson Alessandro Mantovani Christopher D Byrne Giovanni Targher Source Type: research
